IBM Acquiring Truven Health Analytics For $2.6 Billion And Adding It To Watson Health
IBM announced its intent to buy Truven Health Analytics today for a whopping $2.6 billion. It is the fourth major purchase for Watson Health since the unit was established in 2014.
Context & Ripple Effects
By early 2016, Watson Health was being assembled almost entirely through deals: IBM had bought AlchemyAPI to boost the unit in March 2015, signed partnerships with Apple, Johnson & Johnson and Medtronic that April, and added medical imaging via the $1B Merge Healthcare purchase that August. Truven at $2.6B is the largest check yet — the fourth major purchase since the unit was established in 2014.
What makes this worth revisiting is how the story ends: Axios later reported IBM had spent roughly $4B on M&A building Watson Health only to restart efforts to sell the unprofitable division, culminating in a partial sale of image software and data sets to Francisco Partners.
First-order effects
- Truven hands Watson Health a large health-analytics data asset at a price ($2.6B) exceeding the Merge Healthcare deal, deepening IBM's bet that proprietary clinical data is what makes Watson useful to providers and payers.
Second-order effects
- The accumulation raises the stakes for IBM's existing healthcare partners — Apple, J&J and Medtronic — whose 2015 agreements assumed Watson would mature into a platform rather than remain a bundle of acquired businesses.
Third-order effects
- In hindsight this deal is a cautionary data point on capability acquisition: six years after the Truven announcement, IBM was trying to unload a division it had spent ~$4B building, and settled for selling parts — including the imaging software and data sets behind Merge — to Francisco Partners for around $1B.
The trend: Big-tech AI units assembled through acquisition sprees proved harder to integrate than to buy, and Watson Health became the template case for rolling them back up and selling them down.